An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced a virtual fireside chat on January 27 at 10:30 am ET, featuring discussions on eganelisib, an oral immuno-oncology therapy. The event will include Infinity's Executive Leadership Team and is hosted by B. Riley biotech analyst Kalpit Patel.
Infinity is focused on advancing eganelisib through clinical trials, including the pivotal MARIO-4 trial for mTNBC and ongoing studies in combination therapies across various cancer types.
Positive
Scheduled a virtual fireside chat to discuss eganelisib, enhancing visibility among investors.
Continues to advance clinical pipeline with multiple ongoing and planned studies for eganelisib.
Negative
None.
Virtual fireside chat scheduled for Jan 27th at 10:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that it will be highlighted during a virtual oncology fireside chat with B. Riley biotech research analyst Kalpit Patel on Thursday, January 27th at 10:30 am ET. The fireside chat will feature an interactive discussion with Infinity’s Executive Leadership Team, including Adelene Perkins, Chief Executive Officer and Chair, Lawrence Bloch, M.D., J.D., President, and Robert Ilaria, M.D., Chief Medical Officer.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in frontline TNBC and in combination with Tecentriq and Avastin® in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® (nivolumab) in I/O naïve urothelial cancer. MARIO-P is a platform study to evaluate eganelisib to support the initiation of future registration focused studies across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane® is a registered trademark of Abraxis BioScience, LLC.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Avastin® is a registered trademark of Genentech, Inc.
